Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke
Open Access
- 12 July 2012
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (7) , 8670-8678
Abstract
Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.Keywords
This publication has 22 references indexed in Scilit:
- Monocyte Chemoattractant Protein-1-Deficiency Impairs the Expression of IL-6, IL-1β and G-CSF after Transient Focal Ischemia in MicePLOS ONE, 2011
- Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemiaBrain Research, 2010
- Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial CellsCerebrovascular Diseases, 2010
- Invited Article: Searching for oracles?Neurology, 2009
- Associations of Inflammatory and Haemostatic Biomarkers with Poor Outcome in Acute Ischaemic StrokeCerebrovascular Diseases, 2009
- Translational Therapeutics of DipyridamoleArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartanEuropean Journal of Neurology, 2007
- Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in MiceStroke, 2007
- Neutrophil Infiltration Increases Matrix Metalloproteinase-9 in the Ischemic Brain after Occlusion/Reperfusion of the Middle Cerebral Artery in RatsJournal of Cerebral Blood Flow & Metabolism, 2003
- Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytesEuropean Journal of Pharmacology: Molecular Pharmacology, 1992